News · 26 weeks330%
2025-10-262026-04-19
Mix1790d
- SEC Filings9(53%)
- Other4(24%)
- Earnings2(12%)
- Leadership1(6%)
- Insider1(6%)
Latest news
25 items- PRDario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative ResearchFindings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plansStatistically significant improvements in workplace functioning highlight the potential economic value of Dario's digital health solutions for payersNEW YORK, April 20, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in JMIR Formative Research demonstrating meaningful improvements in workplace functioning among participants using Dario's digital behavioral health program. The study, t
- INSIDERSEC Form 3 filed by new insider Palumbo John R3 - DarioHealth Corp. (0001533998) (Issuer)
- SECDarioHealth Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - DarioHealth Corp. (0001533998) (Filer)
- PRDario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial ScalingMr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic valueNEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors. The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling. Mr. Palumbo brings more than 40 ye
- SECSEC Form 424B5 filed by DarioHealth Corp.424B5 - DarioHealth Corp. (0001533998) (Filer)
- SECDarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form EFFECT filed by DarioHealth Corp.EFFECT - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form S-8 filed by DarioHealth Corp.S-8 - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form S-3 filed by DarioHealth Corp.S-3 - DarioHealth Corp. (0001533998) (Filer)
- PRDarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsFourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR") set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-
- SECSEC Form 10-K filed by DarioHealth Corp.10-K - DarioHealth Corp. (0001533998) (Filer)
- PRDarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, March 19th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: Thursday, March19th, 2026, 8:30 a.m. Eastern TimeDial-in Numb
- PRDario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital HealthFindings reinforce that engagement data provide clinical signals directly impacting ROIAnalysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curveNEW YORK, March 10, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in Frontiers in Digital Health demonstrating substantial and sustained blood glucose improvements among users of the Dario platform. The observational study, titled "Machine learning and engagement insights for personalized blood glucose management," analyzed real-world data from 22,414
- PRDario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight ManagementAs oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world successGiven GLP-1 medication expense is one of the fastest-growing cost drivers for payers, Dario enables real-world patient adherence to deliver better long term health outcomes and reduced spending for clients resulting in higher ROI NEW YORK, March 3, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced increasing employer and health plan demand for its oral GLP-1 digital health solution, which is purpose-
- SECAmendment: SEC Form SCHEDULE 13G/A filed by DarioHealth Corp.SCHEDULE 13G/A - DarioHealth Corp. (0001533998) (Subject)
- SECDarioHealth Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - DarioHealth Corp. (0001533998) (Filer)
- SECDarioHealth Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - DarioHealth Corp. (0001533998) (Filer)
- PRDario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based PlatformsGrowing body of peer-reviewed publications and rigorously reviewed conference research reinforces Dario's position as trusted partner for organizations seeking to reduce cost, improve outcomes and simplify digital health delivery NEW YORK, Jan. 21, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that it has surpassed 100 scientific studies, including peer-reviewed journal publications and peer-reviewed conference abstracts, marking a significant milestone in the Company's commitment to delivering rigorously validated outcomes for employers, health plans and their members. Reaching this thresh
- SECSEC Form EFFECT filed by DarioHealth Corp.EFFECT - DarioHealth Corp. (0001533998) (Filer)
- SECAmendment: SEC Form S-3/A filed by DarioHealth Corp.S-3/A - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form DEF 14A filed by DarioHealth Corp.DEF 14A - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form PRE 14A filed by DarioHealth Corp.PRE 14A - DarioHealth Corp. (0001533998) (Filer)
- PRDario Launches DarioIQ™ AI Integration in Dario Health App with Direct-to-Consumer First Version for Hypertension MembersFirst in-market activation of Dario's GenAI roadmap lays clinical and technical foundation for a seamless, conversational AI experience across the entire Dario platform DarioIQ™ reflects years of innovation in data science, engineering and clinical design backed by Dario's proprietary AI models and 13 billion real-world data points, further reinforcing Dario's position as a leader in digital health NEW YORK, Dec. 10, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the launch of the Dario Health app enhanced with DarioIQ™, the Company's new artificial intelligence ("AI") layer, delivered as a di
- PRDario's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR CardioPeer-reviewed JMIR Cardio study demonstrates real-world clinical impact of data-driven digital nudges on hypertension outcomes Data-driven engagement translates to lower health risks and downstream cost savings for Dario clients Results highlight Dario's ability to deliver lasting impact and further cement the Company's position as a proven leader in evidence-based digital care NEW YORK, Dec. 4, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced publication of a new peer-reviewed study in JMIR Cardio demonstrating that data-driven nudges delivered via Dario's digital health platform are associa
- PRDarioHealth Far Exceeds 2025 New Client Target with 79 New Accounts Signed Year-to-Date34 new employer clients added in the past two weeks expected to contribute to H1 2026 revenue Data-driven outcomes drive employer adoption, highlighting Dario's market leadership as partner of choice, underscoring employer confidence, repeatability and scalability NEW YORK, Dec. 2, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that it has secured 34 new employer clients in the past two weeks, reaching a total of 79 clients signed year-to-date, exceeding its 2025 target of 40 new clients by 98%. These new agreements, which collectively represent tens of thousands of covered lives, further vali